BioLineRX
BLRX
20 hedge funds and large institutions have $2.91M invested in BioLineRX in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
11% more funds holding
Funds holding: 18 → 20 (+2)
0.01% less ownership
Funds ownership: 0.02% → 0.01% (-0.01%)
14% less capital invested
Capital invested by funds: $3.37M → $2.91M (-$455K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$84.6K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$65K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$19.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$15.9K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$13.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.03M |
| 2 |
ACM
Altium Capital Management
New York
|
-$542K |
| 3 |
Renaissance Technologies
New York
|
-$99.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.26K |
| 5 |
AWS
Atria Wealth Solutions
New York
|
-$1.97K |
BLRX Hedge Fund Activity: Q1 2023 in Review
20 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2023, worth a combined $2.91M — down 14% from $3.37M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BLRX positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was PVG Asset Management, opening a new position worth an estimated $84.6K. The largest seller was Sabby Management, exiting entirely with an estimated $1.03M sold.
- 20 institutional investors held BioLineRX (BLRX) as of Q1 2023, up from 18 in Q4 2022.
- Funds reported $2.91M of BioLineRX stock for Q1 2023, down 14% quarter-over-quarter.
- 5 funds opened new BioLineRX positions in Q1 2023 and 3 closed out, a net change of +2 holders.
- The largest BioLineRX buyer in Q1 2023 was PVG Asset Management, an estimated $84.6K added.
- The largest BioLineRX seller in Q1 2023 was Sabby Management, an estimated $1.03M sold.
Based on aggregated 13F filings for Q1 2023.